Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta

NCT03852719 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03852719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03852719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
April 17, 2019
Completion date
August 8, 2024
Enrollment
150 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis delta